|
Anti-PD-1 monoclonal antibody Clinical Trials
13 actively recruiting trials across 4 locations
Also known as: Anti-PD-1, Camrelizumab Injection, Opdivo, PD-1 inhibitor, Sintilimab Injection, Tislelizumab Injection, Toripalimab Injection, nivolumab
Other9 trials
Phase 2
Birmingham, Alabama1 trial
First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.
University of Alabama at Birmingham
Phase 1/2
Scottsdale, Arizona1 trial
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
HonorHealth Research Institute
Phase 1/2
Los Angeles, California1 trial
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
Cedars Sinai Medical Center
Phase 1/2
Madison, Wisconsin1 trial
Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC
University of Wisconsin - Madison
Phase 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.